So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes ...
The company continues to improve its pipeline.
Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant “experienced potential drug-induced liver injury,” the company said April 14. In dose ...
Pfizer's dividend yield is so high at least in part because the stock has fallen more than 50% from its 2021 highs. There are a number of reasons for this fall from grace, but one very important one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results